HER2+ early breast cancers where shorter-course trastuzumab could be an option

(European Society for Medical Oncology) Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

ConclusionAFT does not increase breast cancer recurrence, with the possible exception of late LRRs for Luminal A patients, but further clinical and preclinical data are required to better clarify this data. The use of AFT should not be discouraged.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Metformin, a biguanide, is one of the most commonly prescribed treatments for type 2 diabetes and has recently been recommended as a potential drug candidate for advanced cancer therapy. Although Metformin has...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
Publication date: Available online 20 May 2019Source: Trends in Pharmacological SciencesAuthor(s): Mo Yang, John S. SchneeklothRecently, Costales and colleagues (J. Am. Chem. Soc. 2019;141:2960–2974) reported a bivalent small molecule inhibitor of primary miRNA (pri-miR)-515. Perturbation of pri-miR-515 results in the upregulation of HER2 protein levels, rendering HER2– breast cancer cells more sensitive to Herceptin treatment. This strategy represents a novel pharmacological approach to selectively modulating disease-relevant proteins in tumor cells.
Source: Trends in Pharmacological Sciences - Category: Drugs & Pharmacology Source Type: research
ConclusionAlthough well tolerated, the efficacy of everolimus and vinorelbine combination therapy was not superior to vinorelbine monotherapy. There was no correlation between PI3  K mutational status and efficacy.EudracCT No 2011-001024-38, ClinicalTrials.gov No NCT01520103
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractTrace amine-associated receptors are G protein-coupled receptors of which TAAR1 is the most well-studied. Recently, Vattai et al. (J Cancer Res Clin Oncol 143:1637 –1647https://doi.org/10.1007/s00432-017-2420-8,2017) reported that expression of TAAR1 may be a marker of breast cancer (BC) survival, with a positive correlation also suggested between TAAR1 expression and HER2 positivity. Neither a role for TAAR1 in breast tissue, nor in cancer, had previously been suspected. We, therefore, sought to provide independent validation and to further examine these putative relationships. First, a bioinformatic analysi...
Source: Histochemistry and Cell Biology - Category: Biomedical Science Source Type: research
CONCLUSION: MRI features may predict TIL levels in patients with ER-negative HER-2 positive breast cancer, enhancing the ability to diagnose and treat these patients. PMID: 31109192 [PubMed - as supplied by publisher]
Source: Acta Radiologica - Category: Radiology Authors: Tags: Acta Radiol Source Type: research
ConclusionSNB application after PST for breast cancer in node positive patients at presentation is increasing. Pre-operative axillary imaging and tumour biology help identify patients who might be candidates for SNB as a single staging procedure.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Publication date: Available online 18 May 2019Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Zoran CuligAbstractEpithelial to mesencyhmal transition (EMT) has a central role in tumor metastasis and progression. EMT is regulated by several growth factors and pro-inflammatory cytokines. The most important role in this regulation could be attributed to transforming growth factor-β (TGF-β). In breast cancer, TGF-β effect on EMT could be potentiated by Fos-related antigen, oncogene HER2, epidermal growth factor, or mitogen-activated protein kinase kinase 5 – extracellular-re...
Source: Biochimica et Biophysica Acta (BBA) Molecular Cell Research - Category: Molecular Biology Source Type: research
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Opinion statementOral inhibitors of CDK4/6 have been shown to increase response rates and prolong disease control when combined with endocrine therapy in hormone-responsive (HR+) HER2-negative advanced breast cancer. Palbociclib, ribociclib and abemaciclib are all approved in combination with non-steroidal aromatase inhibitors in first-line therapy for post-menopausal women, with a 40 –45% improvement in progression-free survival seen with the addition of any of these CDK4/6 inhibitors. Additional approved indications, including first- and second-line combination therapy for pre-menopausal women, combination with ful...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin | Politics | Toxicology | Women